(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The Best Design Bloggers for Style Motivation - 2'Backward and upward and tilted': Spaceflight causes astronauts' brains to shift inside their skulls
- 3Midlife weight gain can start long before menopause – but you can take steps early on to help your body weather the hormonal shift
- 4Are Iraqi militias crossing into Iran to support Iran's war effort?
- 5How many ships have been attacked in the Gulf since start of Iran war?
- 10 Demonstrated Tips to Expand Your New Android Cell phone: A Thorough Aide
- Knesset sets special panel to fast-track Karhi’s communications reform
- 5 Advancement Developments in Biotechnology
- Early Thanksgiving week forecast: Where Americans can expect cold, rain and snow for the holiday
- Roman around the Christmas tree | Space photo of the day for Dec. 25, 2025
- More Than 110 New Species Discovered In Deep Waters Off Australia
- Geomagnetic storm grounds launch of Mars space weather satellites
- Find the Mysteries of Powerful Using time productively: Augmenting Efficiency and Proficiency
- 5 Movies That Leaving an Imprint with Inventive Innovation
